Additive melanoma suppression with intralesional phospholipid conjugated TLR7 agonists and systemic IL-2

OBJECTIVE: There remains a compelling need for the development of treatments for unresectable melanoma. Agents that stimulate the innate immune response could provide advantages for cell based therapies. However there are conflicting reports concerning whether Toll-like receptor (TLR) signaling cont...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hayashi, Tomoko, Chan, Michael, Norton, John T., Wu, Christina C.N., Yao, Shiyin, Cottam, Howard B., Tawatao, Rommel I., Corr, Maripat, Carson, Dennis A, Daniels, Gregory A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057341/
https://ncbi.nlm.nih.gov/pubmed/21030882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0b013e328340ce6c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares